ANNOUNCEMENT
1ST INTERNATIONAL MEETING ON
HEPATITIS CURE &
ERADICATION
TORONTO, CANADA • 5- 6 NOVEMBER 2014
ORGANIZING COMMITTEE
Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, the Netherlands
DEAR COLLEAGUES,
MEETING OBJECTIVE
Henry Chan, MD
Chinese University of Hong Kong, China
It is our pleasure to announce the 1st International Hepatitis Cure &
Eradication Meeting 2014, to be held on 5 and 6 Novemer 2014 in Toronto,
Canada.
To decrease the burden of the disease,
to simplify treatment and to cure and
eradicate Hepatitis
Jordan Feld, MD
University of Toronto, Canada
The field of Hepatitis treatment is undergoing major changes and is on
the verge of a paradigm shift. The many new treatment options that are
becoming available through the introduction of Direct Acting Antivirals are
providing great hopes for decreasing the burden of disease, simplifying
treatment and ultimately eradication and cure of Viral Hepatitis B and C.
Harry Janssen, MD
University of Toronto, Canada
Pietro Lampertico, MD, PhD
University of Milan, Italy
Stanley Lemon, MD
University of North Carolina, Chapel Hill, USA
In order to reach this end goal of cure for Hepatitis, many studies still
need to be performed and interpreted. It is therefore that we have started
preparations for this new workshop, to be held in Toronto, Canada on 5
and 6 November 2014, preceding the AASLD in Boston, USA.
The format of this workshop will consist of a two-day translational
and public health meeting with invited lectures. In order to ascertain
an interactive workshop setting, much time will be allocated to Q&A
sessions, roundtable discussions and debates.
TARGET AUDIENCE
This initiative brings together clinicians,
academic reseachers, policy makers and
industry representatives supporting the
goal of this meeting.
MEETING VENUE
Radisson Admiral Toronto Harbourfront
249 Queens Quay W, Toronto
ON M5J 2N5, Canada
We look forward to welcoming you to the workshop in November 2014!
Stephen Locarnini, BSC, PHD, MBBS, FRC
Victorian Infectious Diseases Reference Laboratory,
Melbourne, Australia
Jürgen Rockstroh, MD
University of Bonn, Germany
GOAL: DEFINING THE PATHWAY FORWARD TO CURE
AND ERADICATE VIRAL HEPATITIS FROM THE WORLD
Lai Wei, MD
Peking University, China
Registration and information: www. virology-education.com
PROGRAM
Day 1 - November 5
1:00 PM
Introduction: Goals of the HepCure Meeting - Harry Janssen, MD - University of Toronto, Canada
Opening session
1:15 PM
Keynote Lecture: The Evolution of Treating Viral Hepatitis - Ray Schinazi, PhD, DSc - Emory
University/VA Medical Center, USA
1:45 PM
Towards a Cure for Hepatitis B: Inspiration from HIV - Daria Hazuda - Merck, USA (t.b.c)
2:15 PM
Discussion
Session 1: Hepatitis B – from Control to Cure
2:45 PM
State of the Art of Hepatitis B Treatment - Pietro Lampertico, MD, PhD - University of Milan, Italy
3:15 PM
New HBV Treatment Options on the Horizon - Harry Janssen, MD - University of Toronto, Canada
3:45 PM
Does viral cure prevent HCC development - Henry Chan, MD - Chinese University of Hong Kong,
China
4:15 PM
Discussion
4:45 PM
Coffee Break
5:15 PM
How to Achieve Cure in HBV: A Virological Perspective - Stephen Locarnini, BSC, PhD, MBBS, FRC Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
5:35 PM
How to Achieve Cure in HBV: An Immunological Perspective - Mala Maini - University College
London, United Kingdom (t.b.c.)
5:55 PM
How to Achieve Cure in HBV: A Clinical Perspective - Heiner Wedemeyer, MD - Medical School,
Hannover, Germany
6:15 PM
Round Table Discussion: HBV from Control to Cure
Chairs: Stephen Locarnini & Harry Janssen
7:15 PM
End of day 1
11:00 AM
An HCV vaccine: can we get there? - Andrea Cox, MD, PhD - Johns Hopkins University School of
Medicine, Baltimore, USA
11:30 AM
Role of virus control in development of HCC - Morris Sherman, MB, BCh, PhD, FRCP - University of
Toronto, Canada
12:00 PM
Round Table Discussion: Challenges Curing Patients
Chair: Jordan Feld
12:30 PM
Lunch Break
Session 3: From Cure to Eradication
1:30 PM
Current Prevention Strategies of Viral Hepatitis - Kiren Mitruka, MD, MPH - Centers for Disease
Control and Prevention, Atlanta, USA
1:50 PM
Global underdiagnosis of Viral Hepatitis - Mel Krajden, MD, FRCPC - BC Centre for Disease Control,
Vancouver, Canada
2:10 PM
Linkage of Care - Shruti Mehta, PhD, MPH - Johns Hopkins Bloomberg School of Public Health,
Baltimore, USA
Treatment as Prevention
2:30 PM
Experience in HIV - Julio Montaner, MD, FRCPC, FCCP - University of British Columbia, Vancouver,
Canada
2:50 PM
Challenges in HBV - Wei Lai, MD - Peking University People's Hospital, Beijing, China
3:00 PM
Challenges in HCV - Greg Dore, MBBS, PhD, FRACP, MPH - Kirby Institute, UNSW Australia, Sydney
3:20 PM
Discussion
3:45 PM
Coffee Break
Delivering Therapy on an Individual & Society Level
4:00 PM
Integrative talk - Charles Gore - World Hepatitis Alliance, London, United Kingdom
4:20 PM
The Role of
* WHO - Stefan Wiktor, MD - World Health Organization, Geneva, Switzerland
Day 2 - November 6
* Pharmaceutical industry - James Rooney, MD - Gilead Sciences, USA
Session 2: Hepatitis C – Curing the Patient
* Medical community - Geoffrey Dusheiko, MD, MB, BCh - Royal Free Hospital, London, United
Kingdom
8:30 AM
Abbvie Supported Session
9:30 AM
Current Treatment Challenges - Thomas Berg, MD - University of Leipzig, Germany
* Patients - Charles Gore, World Hepatitis Alliance, London, United Kingdom
* CDC USA - Kiren Mitruka, MD, MPH - Centers for Disease Control and Prevention, Atlanta, USA
10:00 AM
Treatment in Special Clinical Populations - Jordan Feld, MD - University of Toronto, Canada
5:00 PM
Roundtable Discussion: all stakeholders
10:30 AM
Coffee Break
6:00 PM
Presentation of the Toronto Declaration on Global Eradication of Hepatitis
6:30 PM
Program Adjournment - Jordan Feld, MD - University of Toronto, Canada
www.virology-education.com